Treatment of Benign Prostatic Hyperplasia by Ultrasound-Guided Botulinum Toxin Type A Injection

详细信息    查看全文

• 作者：Xu-Dong Ding ; Huan-Xian Chen ; Hong-Qiong Xiao ; Wei Wang…
• 关键词：Benign prostatic hyperplasia ; Botulinum toxin type A ; Ultrasound ; guided therapy
• 刊名：Cell Biochemistry and Biophysics
• 出版年：2015
• 出版时间：November 2015
• 年：2015
• 卷：73
• 期：2
• 页码：357-359
• 全文大小：322 KB
• 参考文献：1.AUA Practice Guidelines Committee. (2003). AUA guideline on the management of benign prostatic hyperplasia: diagnosis and treatment recommendations. Journal of Urology, 170, 530鈥?47.CrossRef
  2.Wasserman, N. F. (2006). Benign prostatic hyperplasia: a review and ultrasound classification. Radiologic Clinics of North America, 44, 689鈥?10.CrossRef PubMed
  3.Clifford, G. M., & Farmer, R. D. T. (2000). Medical therapy for benign prostatic hyperplasia: a review of the literature. European Urology, 38, 2鈥?9.CrossRef PubMed
  4.de La Rosette, J. J. M. C. H., Alivizatos, G., Madersbacher, S., Perachino, M., Thomas, D., Desgrandchamps, F., et al. (2001). EAU guidelines on benign prostatic hyperplasia (BPH). European Urology, 40, 256鈥?64.CrossRef
  5.Lu-Yao, G. L., Barry, M. J., Chang, C. H., Wasson, J. H., & Wennberg, J. E. (1994). Transurethral resection of the prostate among medicare beneficiaries in the United States: time trends and outcomes. Urology, 44, 692鈥?99.CrossRef PubMed
  6.Lim, S. K., & Quek, P. L. C. (2008). Intraprostatic and bladder-neck injection of botulinum A toxin in the treatment of males with bladder-neck dyssynergia: a pilot study. European Urology, 53, 620鈥?27.CrossRef PubMed
  7.Welch, M. J., Purkiss, J. R., & Foster, K. A. (2000). Sensitivity of embryonic rat dorsal root ganglia neurons to clostridium botulinum neurotoxins. Toxicon, 38, 245鈥?58.CrossRef PubMed
  8.Chuang, Y. C., & Chancellor, M. B. (2006). The application of botulinum toxin in the prostate. Journal of Urology, 176, 2375鈥?382.CrossRef PubMed
  9.Smith, C. P., & Chancellor, M. B. (2004). Emerging role of botulinum toxin in the management of voiding dysfunction. Journal of Urology, 171, 2128鈥?137.CrossRef PubMed
  10.Wyndaele, J. J., & Van Dromme, S. A. (2002). Muscular weakness as side effects of botulinum toxin injection for neurogenic detrusor overactivity. Spinal Cord, 40, 599鈥?00.CrossRef PubMed
  11.Ding, X. D., Chen, H. X., Wang, W., et al. (2014). Effectiveness of the combination of botulinum toxin type A and bare-foot orthoses in treating lower limbs spasm in patients with hemiplegia after stroke. Chinese Journal of Physical Medicine Rehabilitation, 36, 349鈥?52.
  12.Flynn, M. K., Amundsen, C. L., Pemvich, M., Liu, F., & Webster, G. D. (2009). Outcome of a randomized, double-blind, placebo controlled trial of botulinum A toxin for refractory overactive bladder. Journal of Urology, 181, 2608鈥?615.PubMed Central CrossRef PubMed
  
• 作者单位：Xu-Dong Ding (1)
  Huan-Xian Chen (1)
  Hong-Qiong Xiao (1)
  Wei Wang (1)
  Zhi-Gang Ding (1)
  Gui-Bin Zhang (1)
  Du-Guan Fu (1)
  
  1. Department of Rehabilitation, Xiangyang Hospital Affiliated to Hubei University of Medicine, Xiangyang, Hubei, China
  
• 刊物主题：Biochemistry, general; Pharmacology/Toxicology; Biotechnology; Cell Biology; Biophysics and Biological Physics;
• 出版者：Springer US
• ISSN：1559-0283

文摘

The objective of the study was to determine the efficacy of ultrasound-guided botulinum toxin type A (BTX-A) injection in the treatment of benign prostatic hyperplasia (BPH). In the 32 patients clinically diagnosed with BPH, 200 IU BTX-A was injected into five points at the lateral and middle lobes of the prostate under the guidance of ultrasound using a balloon dilatational device. The international prostate symptom score, quality of life score, maximum flow rate, post-void residual urine volume, prostate-specific antigen, and prostate volume were determined before treatment and at 1, 3, 6, and 12 months after treatment. All clinical symptoms and indicators were remarkably improved 1 month after the treatment and reached the optimal levels at 6 months post-treatment. This improvement of clinical parameters was maintained for a period of at least 1 year. Ultrasound-guided BTX-A injection was found to be safe and effective in the management of BPH. Keywords Benign prostatic hyperplasia Botulinum toxin type A Ultrasound-guided therapy